Perrigo Company PLC (N:PRGO)
Business Focus: Pharmaceuticals
| Sector: Healthcare | Industry: Pharmaceuticals |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | The Sharp Building Hogan Place, Dublin 2 DUBLIN D02 TY74 |
| Tel: | 1-269-6863373 |
| Website: | https://www.perrigo.com |
| IR: | See website |
| Key People | ||
| Patrick Lockwood-Taylor President, Chief Executive Officer, Director | Grainne Quinn Executive Vice President, Chief Medical Officer | Eduardo Guarita Bezerra Chief Financial Officer, Executive Vice President |
| Robert Willis Chief Human Resource Officer, Executive Vice President | Thomas M. Farrington Executive Vice President, Chief Information Officer | Alison Ives Executive Vice President, Chief Scientific Officer |
| Kyle L. Hanson Executive Vice President, General Counsel, Company Secretary | Svend Andersen Executive Vice President, President - Consumer Self-Care International | Ronald Craig Janish Executive Vice President - Global Operations and Supply Chain, Chief Transformation Officer | Roberto Khoury Executive Vice President, President, Consumer Self-Care International |
| Business Overview |
| Perrigo Company plc is an Ireland-based provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. The Company's segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises its consumer self-care business (OTC, infant formula, and oral care categories, and contract manufacturing) in the United States and Canada, including the HRA Pharma self-care business (Women's Health and Skin-Care categories) in the United States and Canada. The CSCI segment comprises its consumer self-care business in Europe and Australia, which are primarily branded, its store brand business in the United Kingdom and parts of Europe and Asia and includes the HRA Pharma self-care business (Women's Health, Skin-Care and Rare-Disease categories) in Europe. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, Nutrition and others. |
| Financial Overview |
| For the three months ended 30 March 2024, Perrigo Company PLC revenues decreased 8% to $1.08B. Net income before extraordinary items totaled $4.1M vs. loss of $1.1M. Revenues reflect CSCA segment decrease of 16% to $644.1M, United States segment decrease of 16% to $632.3M. Net Income reflects CSCI segment income increase of 24% to $26.5M. Dividend per share increased from $0.27 to $1.10. |
| Employees: | 9,140 as of Dec 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $7,569M as of Mar 30, 2024 |
| Annual revenue (TTM): | $4,556M as of Mar 30, 2024 |
| EBITDA (TTM): | $573.30M as of Mar 30, 2024 |
| Net annual income (TTM): | $0.70M as of Mar 30, 2024 |
| Free cash flow (TTM): | $130.00M as of Mar 30, 2024 |
| Net Debt Last Fiscal Year: | $3,407M as of Mar 30, 2024 |
| Shares outstanding: | 136,320,433 as of May 3, 2024 |
| Index Membership: | S&P 400 Mid Cap |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.